Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNU6-1331P** is a human pseudogene arising from the U6 small nuclear RNA gene family. Pseudogenes of U6 snRNA are common in vertebrate genomes, often existing as non-coding genomic elements resulting from gene duplication or retrotransposition events. U6 small nuclear RNA itself is essential for the splicing of pre-mRNA and is part of the spliceosomal machinery[1][3]. However, RNU6-1331P does not code for a functional RNA involved in splicing or other cell regulatory activities. Most U6 pseudogenes are not transcribed into functional RNAs, although some pseudogenes can exert regulatory effects, such as miRNA decoy activity or by generating non-coding RNAs; to date, there is no evidence suggesting that RNU6-1331P possesses these functions[4][5]. RNU6-1331P is not considered a drug target or a disease biomarker, and there are no known disease associations or therapeutic concerns related to this pseudogene. Key notes: - RNU6-1331P is *not* a functional receptor, enzyme, transporter, transcription factor, or any protein target. - As a pseudogene from a small nuclear RNA gene family, it is primarily of genomic and evolutionary interest. - No literature supports involvement in diseases, biomarker status, or druggability; generic pseudogene regulatory mechanisms are not specific to this locus. If more information about the biological role or clinical relevance of this specific pseudogene becomes available in future research, the scientific consensus may change, but current information does not support a functional or target role for RNU6-1331P.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1331, pseudogene (RNU6-1331P).